{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:53Z","timestamp":1789726253547,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jiac.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T07:30:29Z","timestamp":1651563029000},"page":"1148-1152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-4500","authenticated-orcid":false,"given":"Noha","family":"Ashy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layan","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Alkhamisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Alradadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Eljaaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"49","key":"10.1016\/j.jiac.2022.04.020_bib1","first-page":"838","article-title":"Community-acquired pneumonia in adults","volume":"114","author":"Kolditz","year":"2017","journal-title":"Dtsch Arztebl Int"},{"issue":"328","key":"10.1016\/j.jiac.2022.04.020_bib2","first-page":"1","article-title":"Mortality in the United States, 2017","author":"Murphy","year":"2018","journal-title":"NCHS Data Brief"},{"issue":"7","key":"10.1016\/j.jiac.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jiac.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"18","key":"10.1016\/j.jiac.2022.04.020_bib5","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bph.13936","article-title":"The macrolide antibiotic renaissance","volume":"174","author":"Dinos","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.jiac.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12879-017-2495-5","article-title":"Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis","volume":"17","author":"Eljaaly","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"19","key":"10.1016\/j.jiac.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.3390\/jcm10194321","article-title":"Efficacy of empiric antibiotic coverage in community-acquired pneumonia associated with each atypical bacteria: a meta-analysis","volume":"10","author":"Eljaaly","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.jiac.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/BF01975833","article-title":"Spectrum of activity of azithromycin","volume":"10","author":"Williams","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jsps.2022.02.004","article-title":"The effect of erythromycin and clarithromycin versus azithromycin on serum valproate concentration","volume":"30","author":"Albanji","year":"2022","journal-title":"Saudi Pharmaceut J"},{"issue":"5","key":"10.1016\/j.jiac.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cmi.2018.08.002","article-title":"Contraindicated drug-drug interactions associated with oral antimicrobial agents prescribed in the ambulatory care setting in the United States","volume":"25","author":"Eljaaly","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.jiac.2022.04.020_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2307\/30147135","article-title":"Azithromycin and clarithromycin: overview and comparison with erythromycin","volume":"13","author":"Whitman","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"10.1016\/j.jiac.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10180","article-title":"Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community\u2010acquired pneumonia in children","volume":"35","author":"Kogan","year":"2003","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jiac.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2019.1680116","volume":"23","author":"Eljaaly","year":"2020","journal-title":"J Chemother"},{"issue":"Suppl A","key":"10.1016\/j.jiac.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/27.suppl_A.117","article-title":"A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia","volume":"27","author":"Anderson","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2022.04.020_bib15","first-page":"302","article-title":"A randomized comparative study on the safety and efficacy of clarithromycin and erythromycin in treating community-acquired pneumonia","volume":"55","author":"Jang","year":"1995","journal-title":"Zhonghua Yixue Zazhi"},{"issue":"3","key":"10.1016\/j.jiac.2022.04.020_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.103.3.697","article-title":"Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group","volume":"103","author":"Chien","year":"1993","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jiac.2022.04.020_bib17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3349\/ymj.2000.41.3.340","article-title":"A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia","volume":"41","author":"Hatipoglu","year":"2000","journal-title":"Yonsei Med J"},{"issue":"3","key":"10.1016\/j.jiac.2022.04.020_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/34.3.343","article-title":"In-vitro activity of quinolones and macrolides against mycobacteria","volume":"34","author":"Yew","year":"1994","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.jiac.2022.04.020_bib20","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jiac.2022.04.020_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1128\/AAC.34.7.1407","article-title":"Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans","volume":"34","author":"Hardy","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2022.04.020_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0090-9556(25)08537-X","article-title":"Metabolism and disposition of clarithromycin in man","volume":"18","author":"Ferrero","year":"1990","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.jiac.2022.04.020_bib23","first-page":"148","article-title":"Pharmacokinetic properties of clarithromycin: a comparison with erythromycin and azithromycin","volume":"4","author":"Lebel","year":"1993","journal-title":"Can J Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2022.04.020_bib24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2165\/00003495-199753060-00006","article-title":"Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients","volume":"53","author":"Langtry","year":"1997","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jiac.2022.04.020_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0738-1751(87)90002-5","article-title":"The macrolide revival: thirty five years after erythromycin","volume":"4","author":"Fernandes","year":"1987","journal-title":"Antimicrob Newsl"},{"issue":"12","key":"10.1016\/j.jiac.2022.04.020_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s100960050201","article-title":"Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group","volume":"17","author":"O'Doherty","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2022.04.020_bib27","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1378\/chest.128.4.2230","article-title":"Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults","volume":"128","author":"Drehobl","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jiac.2022.04.020_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1179\/joc.2004.16.1.102","article-title":"Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults","volume":"16","author":"Sopena","year":"2004","journal-title":"J Chemother"},{"issue":"3","key":"10.1016\/j.jiac.2022.04.020_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.95.08030398","article-title":"Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia","volume":"8","author":"Rizzato","year":"1995","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jiac.2022.04.020_bib30","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archinte.160.9.1294","article-title":"Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial","volume":"160","author":"Vergis","year":"2000","journal-title":"Arch Intern Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X22001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:04:57Z","timestamp":1761159897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X22001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1341321X22001349"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2022.04.020","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}